➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Medtronic
Merck
Moodys
McKesson

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

ASTELLAS Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for ASTELLAS
International Patents:303
US Patents:12
Tradenames:19
Ingredients:14
NDAs:35

Drugs and US Patents for ASTELLAS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas VESICARE LS solifenacin succinate SUSPENSION;ORAL 209529-001 May 26, 2020 RX Yes Yes   Get Started for $10   Get Started for $10
Astellas AMBISOME amphotericin b INJECTABLE, LIPOSOMAL;INJECTION 050740-001 Aug 11, 1997 RX Yes Yes   Get Started for $10   Get Started for $10
Astellas CRESEMBA isavuconazonium sulfate CAPSULE;ORAL 207500-001 Mar 6, 2015 RX Yes Yes   Get Started for $10   Get Started for $10
Astellas CRESEMBA isavuconazonium sulfate CAPSULE;ORAL 207500-001 Mar 6, 2015 RX Yes Yes   Get Started for $10   Get Started for $10
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-002 Mar 16, 2005 AP RX Yes Yes   Get Started for $10   Get Started for $10
Astellas PROGRAF tacrolimus CAPSULE;ORAL 050708-003 Aug 24, 1998 AB RX Yes No   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ASTELLAS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-002 Mar 16, 2005 5,376,634   Get Started for $10
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 7,655,637   Get Started for $10
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 7,144,872   Get Started for $10
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-003 Jun 27, 2006 6,265,536   Get Started for $10
Astellas ASTAGRAF XL tacrolimus CAPSULE, EXTENDED RELEASE;ORAL 204096-002 Jul 19, 2013 6,884,433   Get Started for $10
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 8,106,029   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 40 mg ➤ Subscribe 2016-08-31
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 2005-04-18
➤ Subscribe Injection 0.08 mg/mL, 5 mL vial ➤ Subscribe 2012-04-10
➤ Subscribe Extended-release Capsules 0.5 mg, 1 mg, and 5 mg ➤ Subscribe 2013-11-15
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2014-06-16
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 2005-04-16
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2009-04-08

Supplementary Protection Certificates for ASTELLAS Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1893196 491 Finland   Get Started for $10
1189916 11C0004 France   Get Started for $10 PRODUCT NAME: REGADENOSON ET SES SELS; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
1189916 CA 2011 00005 Denmark   Get Started for $10 PRODUCT NAME: REGADENOSON OG SALTE DERAF
2428508 CA 2020 00006 Denmark   Get Started for $10 PRODUCT NAME: GILTERITINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/19/1399 20191028
1189916 392 Finland   Get Started for $10
2428508 20C1003 France   Get Started for $10 PRODUCT NAME: GILTERITINIB OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/19/1399 20191028
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Harvard Business School
Johnson and Johnson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.